{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:11:58Z","timestamp":1779250318605,"version":"3.51.4"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ahj.2026.107400","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T23:02:58Z","timestamp":1772319778000},"page":"107400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rationale, design, and baseline characteristicss of the effect of PCSK9 inhibition on cardiovascular risk in treated HIV infection: EPIC-HIV randomized clinical trial"],"prefix":"10.1016","volume":"297","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7612-3352","authenticated-orcid":false,"given":"Matthew S.","family":"Durstenfeld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Levkova-Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Schaffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shady","family":"Abohashem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael T.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irini","family":"Sereti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven G.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Tawakol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscilla Y.","family":"Hsue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2026.107400_bib0001","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis","volume":"138","author":"Shah","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107400_bib0002","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/QAI.0000000000001450","article-title":"Increased risk of myocardial infarction in HIV-infected individuals in North America compared with the general population","volume":"75","author":"Drozd","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ahj.2026.107400_bib0003","first-page":"1045","article-title":"Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome","volume":"74","author":"Grunfeld","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ahj.2026.107400_bib0004","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1086\/317541","article-title":"Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy","volume":"32","author":"Hadigan","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ahj.2026.107400_bib0005","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/00002030-200305230-00010","article-title":"Cardiovascular disease risk factors in HIV patients\u2013association with antiretroviral therapy. Results from the DAD study","volume":"17","author":"Friis-Moller","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.ahj.2026.107400_bib0006","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1001\/jama.289.22.2978","article-title":"Impact of HIV infection and HAART on serum lipids in men","volume":"289","author":"Riddler","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2026.107400_bib0007","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107400_bib0008","first-page":"249","article-title":"Lipid abnormalities in persons living with HIV infection","volume":"35","author":"Waters","year":"2019","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ahj.2026.107400_bib0009","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Cholesterol Treatment Trialists C: efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170\u2008000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107400_bib0010","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107400_bib0011","doi-asserted-by":"crossref","first-page":"847","DOI":"10.7326\/ANNALS-24-03564","article-title":"Statin therapy as primary prevention for persons with HIV: a synopsis of recommendations from the U.S. Department of Health and Human Services Antiretroviral Treatment Guidelines Panel","volume":"178","author":"Beavers","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2026.107400_bib0012","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.1016\/S2352-3018(25)00047-5","article-title":"Statin use in HIV: European AIDS Clinical Society guidance for the primary prevention of cardiovascular disease","volume":"12","author":"Alagaratnam","year":"2025","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ahj.2026.107400_bib0013","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Prominent R-I, Investigators S: inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107400_bib0014","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/jamacardio.2023.5661","article-title":"Effects of pitavastatin on coronary artery disease and inflammatory biomarkers in HIV: mechanistic substudy of the REPRIEVE Randomized Clinical Trial","volume":"9","author":"Lu","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2026.107400_bib0015","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/jamacardio.2024.4115","article-title":"Pitavastatin, procollagen pathways, and plaque stabilization in patients with HIV: a secondary analysis of the REPRIEVE randomized clinical trial","volume":"10","author":"Kolossvary","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2026.107400_bib0016","doi-asserted-by":"crossref","DOI":"10.1172\/JCI196021","article-title":"Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV","volume":"135","author":"Kolossvary","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ahj.2026.107400_bib0017","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107400_bib0018","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107400_bib0019","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O'Donoghue","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107400_bib0020","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2012.6698","article-title":"Arterial inflammation in patients with HIV","volume":"308","author":"Subramanian","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2026.107400_bib0021","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamacardio.2016.4728","article-title":"Association of arterial and lymph node inflammation with distinct inflammatory pathways in human immunodeficiency virus infection","volume":"2","author":"Tawakol","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2026.107400_bib0022","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/QAI.0000000000000138","article-title":"Increased arterial inflammation relates to high-risk coronary plaque morphology in HIV-infected patients","volume":"66","author":"Tawakol","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ahj.2026.107400_bib0023","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.jacc.2006.03.069","article-title":"Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography","volume":"48","author":"Tahara","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107400_bib0024","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00259-011-1994-7","article-title":"The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers","volume":"39","author":"Wu","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ahj.2026.107400_bib0025","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jacc.2013.04.066","article-title":"Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography\/computed tomography feasibility study","volume":"62","author":"Tawakol","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107400_bib0026","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.004195","article-title":"Coronary plaque morphology and the anti-inflammatory impact of atorvastatin: a multicenter 18F-fluorodeoxyglucose positron emission tomographic\/computed tomographic study","volume":"9","author":"Singh","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.ahj.2026.107400_bib0027","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.jacc.2014.01.088","article-title":"Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia","volume":"64","author":"van Wijk","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107400_bib0028","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1007\/s12350-021-02830-4","article-title":"Anti-inflammatory effect of rosuvastatin in patients with HIV infection: an FDG-PET pilot study","volume":"29","author":"Boczar","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.ahj.2026.107400_bib0029","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2352-3018(14)00032-0","article-title":"Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Lo","year":"2015","journal-title":"Lancet HIV"},{"issue":"6 Pt 1","key":"10.1016\/j.ahj.2026.107400_bib0030","article-title":"Coronary plaque, inflammation, subclinical myocardial injury, and major adverse cardiovascular events in the REPRIEVE Substudy","volume":"4","author":"Lu","year":"2025","journal-title":"JACC Adv"},{"key":"10.1016\/j.ahj.2026.107400_bib0031","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1097\/QAD.0b013e32832e7140","article-title":"Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients","volume":"23","author":"Hsue","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.ahj.2026.107400_bib0032","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.13615","article-title":"Association of endothelial dysfunction and antiretroviral therapy in early HIV infection","volume":"2","author":"Bush","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ahj.2026.107400_bib0033","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.athplu.2024.01.003","article-title":"Endothelial dysfunction and cardiovascular diseases in people living with HIV on specific highly active antiretroviral therapy regimen: a systematic review of clinical studies","volume":"55","author":"Mokoena","year":"2024","journal-title":"Atheroscler Plus"},{"key":"10.1016\/j.ahj.2026.107400_bib0034","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/hrt.2004.056523","article-title":"Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: a randomised double blind crossover trial","volume":"92","author":"Hurlimann","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2026.107400_bib0035","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/cid\/ciy781","article-title":"Safety and impact of low-dose methotrexate on endothelial function and inflammation in individuals with treated human immunodeficiency virus: AIDS Clinical Trials Group Study A5314","volume":"68","author":"Hsue","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ahj.2026.107400_bib0036","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002683","article-title":"HIV and Hepatitis C-coinfected patients have lower low-density lipoprotein cholesterol despite higher proprotein convertase subtilisin kexin 9 (PCSK9): an apparent ``PCSK9-Lipid Paradox\u2019\u2019","volume":"5","author":"Kohli","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2026.107400_bib0037","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1097\/QAD.0000000000001149","article-title":"Plasma IL-6 levels are independently associated with atherosclerosis and mortality in HIV-infected individuals on suppressive antiretroviral therapy","volume":"30","author":"Hsu","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.ahj.2026.107400_bib0038","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009996","article-title":"Coronary endothelial dysfunction is associated with elevated serum PCSK9 levels in people with HIV independent of low-density lipoprotein cholesterol","volume":"7","author":"Leucker","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2026.107400_bib0039","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2026.107400_bib0040","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107400_bib0041","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107400_bib0042","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107400_bib0043","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107400_bib0044","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107400_bib0045","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107400_bib0046","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2026.107400_bib0047","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2514428","article-title":"Evolocumab in patients without a previous myocardial infarction or stroke","volume":"394","author":"Bohula","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107400_bib0048","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/cid\/ciaf207","article-title":"Incidence of statin initiation among people with and without HIV in the US: a prospective observational study","volume":"81","author":"Breger","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ahj.2026.107400_bib0049","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.117.003626","article-title":"Statin discontinuation, reinitiation, and persistence patterns among medicare beneficiaries after myocardial infarction: a cohort study","volume":"10","author":"Booth","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2026.107400_bib0050","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12944-019-1099-z","article-title":"Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis","volume":"18","author":"Toth","year":"2019","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.ahj.2026.107400_bib0051","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.atherosclerosis.2019.07.015","article-title":"PCSK9 inhibition and inflammation: a narrative review","volume":"288","author":"Ruscica","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2026.107400_bib0052","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.jacc.2020.03.025","article-title":"Investigators B: evolocumab in HIV-infected patients with dyslipidemia: primary results of the randomized, double-blind BEIJERINCK study","volume":"75","author":"Boccara","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107400_bib0053","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016263","article-title":"Evolocumab, a PCSK9-monoclonal antibody, rapidly reverses coronary artery endothelial dysfunction in people living with HIV and people with dyslipidemia","volume":"9","author":"Leucker","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2026.107400_bib0054","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s12350-014-0032-0","article-title":"HIV infection and arterial inflammation assessed by (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET): a prospective cross-sectional study","volume":"22","author":"Knudsen","year":"2015","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.ahj.2026.107400_bib0055","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s12350-020-02522-5","article-title":"Pattern of arterial inflammation and inflammatory markers in people living with HIV compared with uninfected people","volume":"29","author":"Taglieri","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.ahj.2026.107400_bib0056","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1016\/j.jacc.2018.09.038","article-title":"IL-1beta inhibition reduces atherosclerotic inflammation in HIV infection","volume":"72","author":"Hsue","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107400_bib0057","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamacardio.2023.4578","article-title":"Mineralocorticoid receptor antagonism by eplerenone and arterial inflammation in HIV: the MIRABELLA HIV study","volume":"9","author":"Srinivasa","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2026.107400_bib0058","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.jacc.2006.05.076","article-title":"In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients","volume":"48","author":"Tawakol","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107400_bib0059","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jacc.2007.05.024","article-title":"(18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials","volume":"50","author":"Rudd","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107400_bib0060","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jcct.2024.05.232","article-title":"Standards for quantitative assessments by coronary computed tomography angiography (CCTA): an expert consensus document of the society of cardiovascular computed tomography (SCCT)","volume":"18","author":"Nieman","year":"2024","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.ahj.2026.107400_bib0061","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jcct.2016.10.002","article-title":"SCCT guidelines for the performance and acquisition of coronary computed tomographic angiography: a report of the society of Cardiovascular Computed Tomography Guidelines Committee: endorsed by the North American Society for Cardiovascular Imaging (NASCI)","volume":"10","author":"Abbara","year":"2016","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.ahj.2026.107400_bib0062","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001267","article-title":"Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis","volume":"3","author":"Hsue","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2026.107400_bib0063","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004243","article-title":"Role of T-cell dysfunction, inflammation, and coagulation in microvascular disease in HIV","volume":"5","author":"Sinha","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2026.107400_bib0064","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021397","article-title":"Effect of HIV-1 infection on Angiopoietin 1 and 2 levels and measures of microvascular and macrovascular endothelial dysfunction","volume":"10","author":"Thakkar","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2026.107400_bib0065","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/ATVBAHA.120.315435","article-title":"Effects of HIV infection on arterial endothelial function: results from a large pooled cohort analysis","volume":"41","author":"Stein","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2026.107400_bib0066","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/QAD.0b013e328352ce54","article-title":"The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease","volume":"26","author":"Ho","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.ahj.2026.107400_bib0067","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jacc.2008.04.049","article-title":"Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) study 5152s","volume":"52","author":"Torriani","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107400_bib0068","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jcmg.2012.02.016","article-title":"Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis","volume":"5","author":"Elkhawad","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ahj.2026.107400_bib0069","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(11)61383-4","article-title":"Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial","volume":"378","author":"Fayad","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107400_bib0070","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jcmg.2013.09.004","article-title":"Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET\/CT imaging","volume":"6","author":"Nitta","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ahj.2026.107400_bib0071","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2015.02.027","article-title":"A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome","volume":"240","author":"Gaztanaga","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2026.107400_bib0072","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.atherosclerosis.2015.03.039","article-title":"The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial","volume":"240","author":"Emami","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2026.107400_bib0073","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.120.012174","article-title":"Effect of liraglutide on arterial inflammation assessed as [(18)F]FDG uptake in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial","volume":"14","author":"Ripa","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.ahj.2026.107400_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112632","article-title":"The effect of trehalose administration on vascular inflammation in patients with coronary artery disease","volume":"147","author":"Jamialahmadi","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ahj.2026.107400_bib0075","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/ard-2022-223302","article-title":"Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis","volume":"82","author":"Solomon","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ahj.2026.107400_bib0076","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/QAD.0000000000003175","article-title":"Investigators of the Bs: long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period","volume":"36","author":"Boccara","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.ahj.2026.107400_bib0077","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.36802","article-title":"Statin discontinuation and cardiovascular events among older people in Denmark","volume":"4","author":"Thompson","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ahj.2026.107400_bib0078","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbi.2023.06.019","article-title":"Psychological stress is associated with arterial inflammation in people living with treated HIV infection","volume":"113","author":"Chow","year":"2023","journal-title":"Brain Behav Immun"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326000621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326000621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:03:39Z","timestamp":1779249819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870326000621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":78,"alternative-id":["S0002870326000621"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107400","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale, design, and baseline characteristicss of the effect of PCSK9 inhibition on cardiovascular risk in treated HIV infection: EPIC-HIV randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107400","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107400"}}